PROGNOSTIC VALUE of HYPERREFLECTIVE FOCI in NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED with BEVACIZUMAB

Retina

Volumn 36, Issue 11, 2016, Pages 2175-2182

  Segal, Ori ^a,b   Barayev, Edward ^a,b   Nemet, Arie Y ^a,b   Geffen, Noa ^a,b   Vainer, Igor ^c   Mimouni, Michael ^c  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Rambam Health Care Campus ^*  (Israel)

Author keywords

AMD; bevacizumab; dots; foci; hyperreflective; location; neovascular; OCT; quantity

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL RETINAL THICKNESS; COHORT ANALYSIS; EPIRETINAL MEMBRANE; FEMALE; HUMAN; HYPERREFLECTIVE FOCI; MAJOR CLINICAL STUDY; MALE; MYOPIA; PROGNOSIS; RETINA DETACHMENT; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; WET MACULAR DEGENERATION; ANTAGONISTS AND INHIBITORS; DIAGNOSTIC IMAGING; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA;

AGED; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; PROGNOSIS; RETINA; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84963533722     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000001033     Document Type: Article

References (22)

1. Castillo MM, Mowatt G, Elders A, et al. Optical coherence tomography for the monitoring of neovascular age-related macular degeneration: a systematic review. Ophthalmology 2015;122:399-406.
2. Kiss CG, Geitzenauer W, Simader C, et al. Evaluation of ranibizumab-induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function. Invest Ophthalmol Vis Sci 2009;50: 2376-2383.
3. Klein R, Knudtson MD, Lee KE, et al. Age-period-cohort effect on the incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2008;115: 1460-1467.
4. Solomon SD, Lindsley K, Vedula SS, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2014;8:CD005139.
5. Coscas G. Tomographie en cohérence optique et dégénérescence maculaire liée à l'âge. Marseille, France: Lamy Edit; 2008.
6. Coscas G, Coscas F, Vismara S, et al. Optical Coherence Tomography in Age-related Macular Degeneration OCT in AMD. Berlin, Heidelberg: Springer Berlin Heidelberg; 2009.
7. Schuman SG, Koreishi AF, Farsiu S, et al. Photoreceptor layer thinning over drusen in eyes with age-related macular degeneration imaged in vivo with spectral-domain optical coherence tomography. Ophthalmology 2009;116:488-496.e482.
8. Akagi-Kurashige Y, Tsujikawa A, Oishi A, et al. Relationship between retinal morphological findings and visual function in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2012;250:1129-1136.
9. Coscas G, De Benedetto U, Coscas F, et al. Hyperreflective dots: a new spectral-domain optical coherence tomography entity for follow-up and prognosis in exudative age-related macular degeneration. Ophthalmologica 2013;229:32-37.
10. Bolz M, Schmidt-Erfurth U, Deak G, et al. Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology 2009; 116:914-920.
11. Omri S, Behar-Cohen F, de Kozak Y, et al. Microglia/macrophages migrate through retinal epithelium barrier by a transcellular route in diabetic retinopathy: role of PKCzeta in the Goto Kakizaki rat model. Am J Pathol 2011;179:942-953.
12. Ogino K, Murakami T, Tsujikawa A, et al. Characteristics of optical coherence tomographic hyperreflective foci in retinal vein occlusion. Retina 2012;32:77-85.
13. Fleckenstein M, Charbel Issa P, Helb HM, et al. High-resolution spectral domain-OCT imaging in geographic atrophy associated with age-related macular degeneration. Invest Ophthalmol Vis Sci 2008;49:4137-4144.
14. Ho J, Witkin AJ, Liu J, et al. Documentation of intraretinal retinal pigment epithelium migration via high-speed ultrahighresolution optical coherence tomography. Ophthalmology 2011;118:687-693.
15. Framme C, Wolf S, Wolf-Schnurrbusch U. Small dense particles in the retina observable by spectral-domain optical coherence tomography in age-related macular degeneration. Invest Ophthalmol Vis Sci 2010;51:5965-5969.
16. Mathew R, Richardson M, Sivaprasad S. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular agerelated macular degeneration treated with ranibizumab. Am J Ophthalmol 2013;155:720-726, 726.e721.
17. Kang JW, Lee H, Chung H, et al. Correlation between optical coherence tomographic hyperreflective foci and visual outcomes after intravitreal bevacizumab for macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2014;252:1413-1421.
18. Melamud A, Stinnett S, Fekrat S. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Am J Ophthalmol 2008;146:91-95.
19. Christenbury JG, Folgar FA, O'Connell RV, et al. Progression of intermediate age-related macular degeneration with proliferation and inner retinal migration of hyperreflective foci. Ophthalmology 2013;120:1038-1045.
20. Pemp B, Deak G, Prager S, et al. Distribution of intraretinal exudates in diabetic macular edema during anti-vascular endothelial growth factor therapy observed by spectral domain optical coherence tomography and fundus photography. Retina 2014;34:2407-2415.
21. Uji A, Murakami T, Nishijima K, et al. Association between hyperreflective foci in the outer retina, status of photoreceptor layer, and visual acuity in diabetic macular edema. Am J Ophthalmol 2012;153:710-717, 717. e711.
22. Simader C, Ritter M, Bolz M, et al. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology 2014;121:1237-1245.